Abstract
We evaluated efficacy and toxicity of the combination of cisplatin, interleulin-2 (IL-2) and interferon (IFN) α or β in patients with metastatic melanoma. Ten patients received cisplatin, 50 or 80 mg/m2 intravenously on day 1, IL-2, 70×104 IU intravenously on days 4-7, 18-22 and IFN β, 300×104 IU subcutaneously or intravenously on every second days (regimen A). Six patients received cisplatin 80 mg/m2 intravenously on day 1, IL-2, 140×104 IU subcutaneously on days 2-8 and IFNα, 500×104 IU subcutaneously on days 2, 4, 6, 8 (regimen B). The induction cycle was repeated on day 29 in both regimens. There was no responder in 6 patients (A) and 4 patients (B) assessed for clinical response. Main toxisities were thrombocytopenia, neutropenia, anemia and nausea. Vitiligo-like depigmentation was seen in one patient, whose disease progressed during the therapy. There were no treatment-related death. These regimens had low activities in the treatment of advanced malignant melanoma. [Skin Cancer (Japan) 2000; 15: 309-314]
